Search Results

Personalis, Inc. announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis’ new Vice President, Customer Experience under Personalis’ 2020 Inducement Plan.

Personalis, Inc., a leader in advanced genomics for precision oncology, reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights.

Personalis, Inc., a leader in advanced genomics for cancer, announced that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Personalis, Inc. and ClearNote Health, Inc., a pioneer in epigenomic technologies, unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine platform.